Company Overview
Company Type: Private Company
Website: jamppharma.com
Number of Employees: 100
Year Founded: 1988
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Jamp Pharma Corporation engages in the development, marketing, and distribution of non-prescription products and branded products of generic drugs to customers in Canada. The company offers antidepressant, antipsychotic, antiemetic, calcium, anti-inflammatory, analgesic, laxatives, vitamins, mineral supplements, digestive enzymes, anti-diarrheal, antihistamine, injectables, antihypertensive, and cholesterol products. It also provides professional services that include training programs on calcium, pharmacy financial management, and human resources management in pharmacy practice. The company offers JAMP Dimethyl Fumarate, which is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability. The company was founded in 1988 and is based in Boucherville, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 33.2
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 100
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1380-230, Newton Street | Boucherville, QC | J4B 5H2 | Canada
Phone: 450-449-1236   Fax: 866-399-9091

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Fonds de solidarité FTQ
Dec-31-2016
Minority
-
Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Laboratoire Suisse Inc.
Laboratoire Suisse Inc. produces and distributes natural health products. The company is based in Brossard, Canada. As of December 17, 2012, Laboratoire Suisse Inc. operates as a subsidiary of Jamp Pharma Corporation.

United States and Canada
Pharmaceuticals
-
-
-
Orimed Pharma Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-31-2016
Dec-31-2016
Private Placement
Target
Jamp Pharma Corporation
Fonds de solidarité FTQ

-
Dec-17-2012
Dec-17-2012
Merger/Acquisition
Buyer
Laboratoire Suisse Inc.
Jamp Pharma Corporation

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-30-2022
Product-Related Announcements
JAMP Pharma Corporation Issues A Voluntary Recall of One Lot of Atorvastatin Tablets, 40 Mg
Aug-09-2022
Product-Related Announcements
Jamp Pharma Corporation Issues Voluntary Recall of One Lot of its Atorvastatin Tablets, 40 Mg, 500-Format for lot MHC1403A (Health Canada's Public Advisory Ra-64446)
Aug-06-2022
Product-Related Announcements
Jamp Pharma Corporation-Atorvastatin 40 Mg Tablets Recalls Due to Risk of Latex Contamination
Apr-13-2022
Product-Related Announcements
JAMP Pharma Group Launches SIMLANDI
Oct-07-2021
Product-Related Announcements
JAMP Pharma Group Improves Drug Access and Affordability for Multiple Sclerosis Patients in Canada


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 20, 2023 05:03 AM
Jamp Pharma Corporation
JAMP Pharma Corp
Reports
26
GlobalData

Jul 27, 2023 07:01 AM
Jamp Pharma Corporation
JAMP Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Jun 28, 2023 04:14 AM
Jamp Pharma Corporation
JAMP Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Jun 16, 2023 02:59 AM
Jamp Pharma Corporation
JAMP Pharma Corp
Reports
26
GlobalData

Mar 29, 2023 04:43 AM
Jamp Pharma Corporation
JAMP Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Mar 14, 2023 01:34 AM
Jamp Pharma Corporation
JAMP Pharma Corp
Reports
26
GlobalData

Dec 13, 2022 05:11 AM
Jamp Pharma Corporation
JAMP Pharma Corp
Reports
27
GlobalData

Nov 10, 2022 07:30 AM
Jamp Pharma Corporation
JAMP Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Sep 26, 2022 07:04 AM
Jamp Pharma Corporation
JAMP Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Sep 23, 2022 06:19 AM
Jamp Pharma Corporation
JAMP Pharma Corp
Reports
26


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
No Key Executives and Professionals exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
